INmune BioINMB -5.02%53 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 53/100 and a GF Value™ of $1.83 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 707 Biotechnology companies, INmune Bio ranks worse than 141442.57% on this metric.
The historical rank and industry rank for INmune Bio's Days Payable or its related term are showing as below:
INMB's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76 * Ranked among companies with meaningful Days Payable only.
INmune Bio's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
INmune Bio Days Payable Related Terms
INmune Bio Days Payable Historical Data
* Premium members only.
The historical data trend for INmune Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, INmune Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where INmune Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
INmune Bio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INmune Bio (INMB) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #999999 out of 707 companies in the Biotechnology industry.
Is INmune Bio's Days Payable too high?
INmune Bio's current Days Payable is 0.00. Based on the distribution chart, INmune Bio ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, INmune Bio has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Days Payable compare to GRDX and VERU?
According to the Biotechnology industry distribution chart, INmune Bio ranks #999999 out of 707 companies for Days Payable. This places INmune Bio in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on INmune Bio and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.83, compared to a current price of $1.42 — trading 22.4% below its estimated fair value. The current Days Payable is 0.00. INmune Bio's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For INmune Bio (INMB), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued.
The current stock price of $1.42 is trading 22.4% below its estimated GF Value™ of $1.83.
GuruFocus considers INmune Bio to be Modestly Undervalued.
Key valuation signals for INMB:
Days Payable: 0.00
GF Value™: $1.83 vs. price of $1.42 (22.4% below fair value)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
53GF Score
Get the complete analysis for INMB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
